ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,999.26
0.40%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Imunon Inc (IMNN)

  7. Imunon Inc (IMNN) News

Imunon (IMNN)

Imunon Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IMNN
DateTimeSourceHeadlineSymbolCompany
23/05/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMNNImunon Inc
20/05/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNNImunon Inc
15/05/202421:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IMNNImunon Inc
15/05/202413:30GlobeNewswire Inc.Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual MeetingNASDAQ:IMNNImunon Inc
14/05/202421:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNNImunon Inc
13/05/202414:00GlobeNewswire Inc.IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine StudyNASDAQ:IMNNImunon Inc
13/05/202413:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMNNImunon Inc
13/05/202413:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNNImunon Inc
13/05/202413:00GlobeNewswire Inc.IMUNON Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IMNNImunon Inc
08/05/202413:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNNImunon Inc
08/05/202413:00GlobeNewswire Inc.IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEONASDAQ:IMNNImunon Inc
06/05/202416:00GlobeNewswire Inc.IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024NASDAQ:IMNNImunon Inc
18/04/202413:30GlobeNewswire Inc.IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101NASDAQ:IMNNImunon Inc
11/04/202413:00GlobeNewswire Inc.IMUNON Reports Compliance with Nasdaq Listing RequirementsNASDAQ:IMNNImunon Inc
28/03/202412:00GlobeNewswire Inc.IMUNON Reports 2023 Financial Results and Provides Business UpdateNASDAQ:IMNNImunon Inc
25/03/202412:30GlobeNewswire Inc.IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating LossesNASDAQ:IMNNImunon Inc
21/03/202421:00GlobeNewswire Inc.IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024NASDAQ:IMNNImunon Inc
13/03/202412:00GlobeNewswire Inc.IMUNON Files IND Application to Begin Human Testing of IMNN-101NASDAQ:IMNNImunon Inc
12/03/202421:00GlobeNewswire Inc.IMUNON Announces Leadership ChangeNASDAQ:IMNNImunon Inc
29/02/202413:30GlobeNewswire Inc.Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5NASDAQ:IMNNImunon Inc
27/02/202413:30GlobeNewswire Inc.Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian CancerNASDAQ:IMNNImunon Inc
22/02/202413:00GlobeNewswire Inc.IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal VaccineNASDAQ:IMNNImunon Inc
09/02/202421:09Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:IMNNImunon Inc
29/12/202321:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNNImunon Inc
20/12/202322:15Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:IMNNImunon Inc
11/12/202321:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNNImunon Inc
11/12/202321:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMNNImunon Inc
11/12/202313:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNNImunon Inc
11/12/202313:30GlobeNewswire Inc.IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IMNNImunon Inc
14/11/202314:00GlobeNewswire Inc.IMUNON’s VP of R&D to Present at the Vaccines Summit-2023NASDAQ:IMNNImunon Inc
 Showing the most relevant articles for your search:NASDAQ:IMNN

Your Recent History

COIN
RATOUSD
The Rare Antiquities Token [OLD]
BIT
S31356
Societe Generale Effekten
TG
PLUN
Plug Power
NASDAQ
TGVC
TG Venture Acquisition
EU
BPHBT
BNP Bond Fh0 Pct 20sep28
NASDAQ
DTIL
Precision BioSciences
NASDAQ
WERN
Werner Enterprises
USOTC
JENGQ
Just Energy (PK)
NYSE
WH
Wyndham Hotels & Resorts
BITMOT
842030
Cipriani Tf 6% Dc25 Amor...
USOTC
NUUU
Rejuvel Bio Sciences (CE)
LSE
QP01
Morg.st.b.v 24
NYSE
AIN
Albany
LSE
KIE
Kier
NASDAQ
OZK
Bank OZK
COIN
ZENFETH
ZENF Token
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved